Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

Authors

Arthur Kavanaugh

Published

March 30, 2009

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Arthritis & Rheumatism

Topics

DOI

10.1002/art.24403

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

Authors

Arthur Kavanaugh

Published

March 30, 2009

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Arthritis & Rheumatism

Topics

DOI

10.1002/art.24403

Paper

Paper

Paper

Paper

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

Supporters

Journal

Topics

DOI

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

Supporters

Journal

Topics

DOI